Neuroprotection in the PNS: Erythropoietin and immunophilin ligands

Ahmet Hoke, Sanjay C. Keswani

Research output: Contribution to journalArticle

Abstract

Many illnesses that affect the peripheral nervous system (PNS) lead to distal axonal degeneration rather than loss of neuronal cell bodies. Strategies aimed at promoting survival of injured neurons (i.e., preventing cell death) may not be applicable to many PNS illnesses. We have developed in vitro and in vivo animal models to study mechanisms of acquired peripheral neuropathies and used these models to evaluate the therapeutic potential of novel compounds. In recent years, erythropoietin (EPO) lias been recognized as a novel neuroprotectant in the central nervous system. In the PNS, we recently showed that Schwann cell-derived EPO acts as an endogenous neuroprotectant and that it is most effective in preventing distal axonal degeneration seen in models of peripheral neuropathy. Similarly, we showed that immunophilin ligands are also neuroprotective in the PNS and prevent axonal degeneration seen in models of peripheral neuropathies. Both EPO and non-immunosuppressive immunophilin ligands are in early clinical development for the treatment of acquired peripheral neuropathies.

Original languageEnglish (US)
Pages (from-to)491-501
Number of pages11
JournalAnnals of the New York Academy of Sciences
Volume1053
DOIs
StatePublished - 2005

Fingerprint

Immunophilins
Peripheral Nervous System
Neurology
Peripheral Nervous System Diseases
Erythropoietin
Ligands
Neuroprotective Agents
Cells
Schwann Cells
Cell death
Cell Death
Central Nervous System
Animal Models
Neurons
Animals
Neuroprotection
Nervous System
Degeneration

Keywords

  • Axonal degeneration
  • EPO
  • Erythropoietin
  • GPI-1046
  • Immunophilin ligands

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Neuroprotection in the PNS : Erythropoietin and immunophilin ligands. / Hoke, Ahmet; Keswani, Sanjay C.

In: Annals of the New York Academy of Sciences, Vol. 1053, 2005, p. 491-501.

Research output: Contribution to journalArticle

@article{be4f701f423741c3875a21a4a7b26308,
title = "Neuroprotection in the PNS: Erythropoietin and immunophilin ligands",
abstract = "Many illnesses that affect the peripheral nervous system (PNS) lead to distal axonal degeneration rather than loss of neuronal cell bodies. Strategies aimed at promoting survival of injured neurons (i.e., preventing cell death) may not be applicable to many PNS illnesses. We have developed in vitro and in vivo animal models to study mechanisms of acquired peripheral neuropathies and used these models to evaluate the therapeutic potential of novel compounds. In recent years, erythropoietin (EPO) lias been recognized as a novel neuroprotectant in the central nervous system. In the PNS, we recently showed that Schwann cell-derived EPO acts as an endogenous neuroprotectant and that it is most effective in preventing distal axonal degeneration seen in models of peripheral neuropathy. Similarly, we showed that immunophilin ligands are also neuroprotective in the PNS and prevent axonal degeneration seen in models of peripheral neuropathies. Both EPO and non-immunosuppressive immunophilin ligands are in early clinical development for the treatment of acquired peripheral neuropathies.",
keywords = "Axonal degeneration, EPO, Erythropoietin, GPI-1046, Immunophilin ligands",
author = "Ahmet Hoke and Keswani, {Sanjay C.}",
year = "2005",
doi = "10.1196/annals.1344.043",
language = "English (US)",
volume = "1053",
pages = "491--501",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Neuroprotection in the PNS

T2 - Erythropoietin and immunophilin ligands

AU - Hoke, Ahmet

AU - Keswani, Sanjay C.

PY - 2005

Y1 - 2005

N2 - Many illnesses that affect the peripheral nervous system (PNS) lead to distal axonal degeneration rather than loss of neuronal cell bodies. Strategies aimed at promoting survival of injured neurons (i.e., preventing cell death) may not be applicable to many PNS illnesses. We have developed in vitro and in vivo animal models to study mechanisms of acquired peripheral neuropathies and used these models to evaluate the therapeutic potential of novel compounds. In recent years, erythropoietin (EPO) lias been recognized as a novel neuroprotectant in the central nervous system. In the PNS, we recently showed that Schwann cell-derived EPO acts as an endogenous neuroprotectant and that it is most effective in preventing distal axonal degeneration seen in models of peripheral neuropathy. Similarly, we showed that immunophilin ligands are also neuroprotective in the PNS and prevent axonal degeneration seen in models of peripheral neuropathies. Both EPO and non-immunosuppressive immunophilin ligands are in early clinical development for the treatment of acquired peripheral neuropathies.

AB - Many illnesses that affect the peripheral nervous system (PNS) lead to distal axonal degeneration rather than loss of neuronal cell bodies. Strategies aimed at promoting survival of injured neurons (i.e., preventing cell death) may not be applicable to many PNS illnesses. We have developed in vitro and in vivo animal models to study mechanisms of acquired peripheral neuropathies and used these models to evaluate the therapeutic potential of novel compounds. In recent years, erythropoietin (EPO) lias been recognized as a novel neuroprotectant in the central nervous system. In the PNS, we recently showed that Schwann cell-derived EPO acts as an endogenous neuroprotectant and that it is most effective in preventing distal axonal degeneration seen in models of peripheral neuropathy. Similarly, we showed that immunophilin ligands are also neuroprotective in the PNS and prevent axonal degeneration seen in models of peripheral neuropathies. Both EPO and non-immunosuppressive immunophilin ligands are in early clinical development for the treatment of acquired peripheral neuropathies.

KW - Axonal degeneration

KW - EPO

KW - Erythropoietin

KW - GPI-1046

KW - Immunophilin ligands

UR - http://www.scopus.com/inward/record.url?scp=29744469444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744469444&partnerID=8YFLogxK

U2 - 10.1196/annals.1344.043

DO - 10.1196/annals.1344.043

M3 - Article

C2 - 16179557

AN - SCOPUS:29744469444

VL - 1053

SP - 491

EP - 501

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -